IL316564A - 7-(Pyrimidine-4-yl)quinolin-4-(1H)-one compounds are being developed as cyclin-dependent kinase inhibitors. - Google Patents
7-(Pyrimidine-4-yl)quinolin-4-(1H)-one compounds are being developed as cyclin-dependent kinase inhibitors.Info
- Publication number
- IL316564A IL316564A IL316564A IL31656424A IL316564A IL 316564 A IL316564 A IL 316564A IL 316564 A IL316564 A IL 316564A IL 31656424 A IL31656424 A IL 31656424A IL 316564 A IL316564 A IL 316564A
- Authority
- IL
- Israel
- Prior art keywords
- quinolin
- pyrimidin
- substituted
- compounds
- kinase inhibitors
- Prior art date
Links
- -1 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds Chemical class 0.000 title 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022090343 | 2022-04-29 | ||
| PCT/CN2023/091482 WO2023208172A1 (en) | 2022-04-29 | 2023-04-28 | Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316564A true IL316564A (en) | 2024-12-01 |
Family
ID=88517884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316564A IL316564A (en) | 2022-04-29 | 2023-04-28 | 7-(Pyrimidine-4-yl)quinolin-4-(1H)-one compounds are being developed as cyclin-dependent kinase inhibitors. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250136586A1 (enExample) |
| EP (1) | EP4514797A4 (enExample) |
| JP (1) | JP2025515483A (enExample) |
| KR (1) | KR20250004015A (enExample) |
| CN (1) | CN119053598A (enExample) |
| AU (1) | AU2023263197A1 (enExample) |
| CA (1) | CA3250944A1 (enExample) |
| CO (1) | CO2024014593A2 (enExample) |
| IL (1) | IL316564A (enExample) |
| MX (1) | MX2024013264A (enExample) |
| WO (1) | WO2023208172A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202513069A (zh) | 2023-07-21 | 2025-04-01 | 美商冰洲石生物科技公司 | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3816119A1 (de) * | 1988-05-11 | 1989-11-23 | Bayer Ag | 7-substituierte chinolon- und naphthyridoncarbonsaeure-derivate |
| US6080757A (en) * | 1996-06-06 | 2000-06-27 | Pfizer Inc | Antibiotic quinolones and derivatives |
| HRP20180483T1 (hr) * | 2011-08-31 | 2018-05-04 | Otsuka Pharmaceutical Co., Ltd. | Spoj kinolona |
| WO2019161224A1 (en) * | 2018-02-15 | 2019-08-22 | GiraFpharma LLC | Heterocyclic compounds as kinase inhibitors |
| CN118286225A (zh) * | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
| CA3150689A1 (en) * | 2019-08-14 | 2021-02-18 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| WO2022236256A1 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
-
2023
- 2023-04-28 WO PCT/CN2023/091482 patent/WO2023208172A1/en not_active Ceased
- 2023-04-28 CN CN202380035007.4A patent/CN119053598A/zh active Pending
- 2023-04-28 KR KR1020247039642A patent/KR20250004015A/ko active Pending
- 2023-04-28 CA CA3250944A patent/CA3250944A1/en active Pending
- 2023-04-28 IL IL316564A patent/IL316564A/en unknown
- 2023-04-28 EP EP23795604.0A patent/EP4514797A4/en active Pending
- 2023-04-28 AU AU2023263197A patent/AU2023263197A1/en active Pending
- 2023-04-28 JP JP2024563508A patent/JP2025515483A/ja active Pending
-
2024
- 2024-10-25 US US18/926,544 patent/US20250136586A1/en active Pending
- 2024-10-25 CO CONC2024/0014593A patent/CO2024014593A2/es unknown
- 2024-10-25 MX MX2024013264A patent/MX2024013264A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119053598A (zh) | 2024-11-29 |
| US20250136586A1 (en) | 2025-05-01 |
| EP4514797A1 (en) | 2025-03-05 |
| CO2024014593A2 (es) | 2024-11-08 |
| AU2023263197A1 (en) | 2024-11-14 |
| CA3250944A1 (en) | 2023-11-02 |
| WO2023208172A1 (en) | 2023-11-02 |
| MX2024013264A (es) | 2024-12-06 |
| KR20250004015A (ko) | 2025-01-07 |
| JP2025515483A (ja) | 2025-05-15 |
| EP4514797A4 (en) | 2026-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278119B (en) | Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors | |
| IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| MX2021011438A (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak. | |
| MY196260A (en) | Small Molecule Inhibitors of the Jak Family Of Kinases | |
| NZ711540A (en) | Fused heterocyclic compounds as protein kinase inhibitors | |
| ZA201200982B (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| WO2010054285A3 (en) | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors | |
| GEP20197050B (en) | Solid state forms of fused heteroaromatic pyrrolidinones | |
| IL316556A (en) | 6-(Pyrimidine-4-yl)quinoline compounds are being developed as cyclin-dependent kinase inhibitors. | |
| EA201991109A1 (ru) | ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| MX2017016772A (es) | Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo. | |
| MX359843B (es) | Sal de derivado de pirazoloquinolina y cristal de la misma. | |
| NZ630416A (en) | Inhibition of phosphorylation of pras40, gsk3-beta or p70s6k1 as a marker for tor kinase inhibitory activity | |
| NZ630580A (en) | 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo,thieno or pyrrolo) [2, 3-d] pyrimidin-4-one derivatives for the treatment of cancer | |
| IL314297A (en) | N3-substituted URACIL compounds as TRPA1 inhibitors | |
| MX390505B (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2 | |
| IL313412A (en) | Heterocyclic compounds as an array of kinase inhibitors | |
| MX2024013264A (es) | Compuestos de 7-(pirimidin-4-il)quinolin-4(1h)-ona sustituidos como inhibidores de cinasas dependientes de ciclina | |
| IL306008A (en) | Pyrimidine derivatives are useful as LRRK2 kinase inhibitors | |
| WO2015019365A8 (en) | N-cyanomethylamides as inhibitors of janus kinase | |
| CA3271837A1 (en) | Substituted quinolines as improved nf-kb-inducing kinase (nik) inhibitors | |
| HK40102616A (en) | Pyrimidine derivatives useful as lrrk2 kinase inhibitors | |
| HK40111600A (en) | Heterocyclic compounds as kit kinase inhibitors | |
| IL319348A (en) | History of heterocyclics as Janus kinase inhibitors |